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Cisplatin  is  one  of the  well-established  anticancer  drugs  being  used  against  a wide  spectrum
of  cancers.  However,  full therapeutic  efﬁcacy  of the  drug  is  limited  due  to development  of
various toxicities  in  the  host.  This  study  examines  the  comparative  therapeutic  effective-
ness  and  toxicities  of cisplatin  alone  and  in combination  of dietary  ascorbic  acid  (AA)  in
ascites  Dalton’s  lymphoma-bearing  mice.  The  ﬁndings  show  that  the  combination  treat-
ment of  mice  with  ascorbic  acid  plus  cisplatin  has  much  better  therapeutic  efﬁcacy  against
murine  ascites  Dalton’s  lymphoma  (DL)  in  comparison  to  cisplatin  alone  and  this  may
involve  a decrease  in  reduced  glutathione  (GSH),  catalase  activity  and  increased  lipid  perox-
idation (LPO)  in Dalton’s  lymphoma  tumor  cells.  At  the  same  time,  combination  treatment
indicates  a protective  role  of  ascorbic  acid  against  cisplatin-induced  tissue  toxicities  (side
effects) in the  hosts.  Cisplatin-induced  histopathological  changes  in  liver,  kidney  and  testes
were decreased  after  combination  treatment.  The  analysis  of  renal  function  test  (RFT),  liver
function  test  (LFT)  and  sperm  abnormalities  also  suggest  an improvement  in these  param-isplatin
alton’s lymphoma
lutathione
ipid peroxidation
oxicity
eters  after  combination  treatment.  Therefore,  it may  be  concluded  that the increased  GSH
level, catalase  activity  and  decreased  LPO  in  the  tissues,  i.e., liver,  kidney  and testes  after
combination  treatment  may  be involved  in its protective  ability  against  cisplatin-induced
tissue  toxicities  in  the host.
©  2015  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
Y-NC-Nthe  CC  B
. Introduction
Cancer and its treatment are among the most critical
ealth issues. According to World Cancer Report released
y the World Health Organization, cancer rates could fur-
her increase to 15 million new cases a year by 2020
1]. Cancer chemotherapy has proven to be an effective
reatment approach which is used either singly or in com-
ination with surgery and/or radiotherapy.
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Cis-diamminedichloroplatinum-(II) or cisplatin is a
platinum-containing inorganic, square–planar complex
which is a well-known anticancer agent being used against
a wide spectrum of malignancies including testicular, head
and neck, ovarian, cervical, non-small cell lung carcinoma,
and many other types of cancer [2–4]. The ability of cis-
platin to react with DNA and formation of cisplatin-DNA
adducts with inter- and intra-strand nuclear DNA cross-
links is suggested to be the main mechanism underlying its
cytotoxic effect [5]. In addition to its interaction with cel-
lular DNA, the changes in various biochemical/enzymatic
parameters, immune response, cell surface structure have
also been observed which have led to the proposal of the
involvement of multistep and multilevel effects of cisplatin
is is an open access article under the CC BY-NC-ND license
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in the tumor cells/host [6]. However, the therapeutic efﬁ-
cacy of cisplatin is often hampered by the development
of various dose-limiting side effects such as nephrotoxi-
city, hepatotoxicity, neurotoxicity, ototoxicity in the hosts
[7] and acquired resistance by cancer cells [8]. In an
attempt to overcome these impediments, the use of cis-
platin in combination with some modulating agents such
as WR2721 [9], quercetin [10] and cordycepin [11] have
been tried with varying degree of success. Further, in an
endeavour to decrease drug-induced toxicity in the host,
the use of anticancer drugs such as cyclophosphamide
[12], paclitaxel [13], arsenic trioxide [14] and doxoru-
bicin [15] in combination with vitamin C have also been
examined.
Ascorbic acid (l-3-ketothreohexuronic acid lactone) or
vitamin C is a water soluble vitamin with antioxidant prop-
erties. Ascorbic acid is an active reducing agent involved
in various biological effects and plays an important role
in the metabolism and detoxiﬁcation of many endogenous
and exogenous compounds [16]. In spite of various reports
showing good therapeutic potential of ascorbic acid against
cancer [17–19] and supporting a role for increased vita-
min  C intake in decreasing the risk of cervical cancer [20],
its deﬁnite use in cancer chemotherapy still remains inad-
equate [21]. Ascorbic acid has been reported to increase
the efﬁcacy of several chemotherapeutic drugs [12,22–24],
though few have shown virtually no beneﬁt from its treat-
ment [25,26]. Some contradictory role of ascorbic acid
has also been suggested in either inhibiting carcinogenesis
[27–29] or enhancing carcinogenesis [30–32]. Some geno-
toxic effects of vitamin C in in vitro test systems have been
demonstrated [33,34] but in in vivo experiments there are
no genotoxic effects by vitamin C.
Thus, considering the inconsistent ﬁndings on the
signiﬁcance of vitamin C in cancer chemotherapy and
its possible protective implication in the hosts, the
present study was undertaken to evaluate the effective-
ness of ascorbic acid in minimizing cisplatin-induced
toxicities/side effects in Dalton’s lymphoma-bearing mice.
The ﬁndings exhibit that the use of ascorbic acid with
cisplatin could be very useful in decreasing cisplatin-
induced toxicities/side effects in the host while showing
better therapeutic efﬁcacy against murine ascites Dalton’s
lymphoma.
2. Materials and methods
2.1. Chemicals
Cisplatin solution (1 mg/ml  of 0.9%, NaCl) was obtained
from Biochem Pharmaceutical Industries, Mumbai, India.
l-ascorbic acid (vitamin C) was purchased from HiMedia
Laboratories, Mumbai, India. Reduced glutathione, 5,5′-
dithiobis-2-nitrobenzoic acid (DTNB) and bovine serum
albumin (BSA) were purchased from Sigma Chemical Co.,
St. Louis, MO,  USA. Ethylenediamine tetra acetic acid
(EDTA) and other chemicals used in the experiments were
of analytical grade and purchased from SRL Pvt. Ltd., Mum-
bai, India. Reports 2 (2015) 489–503
2.2. Animals and tumor maintenance
Inbreed Swiss albino mice colony is being maintained in
the laboratory under conventional conditions at room tem-
perature of 24 ± 2 ◦C with free access to food pellets (Amrut
Laboratory, New Delhi) and drinking water ad libitum.
Ascites Dalton’s lymphoma is being maintained in in vivo in
10–12 weeks old mice by serial intraperitoneal (i.p.) trans-
plantations of approximately 1 × 107 viable tumor cells
per animal (in 0.25 ml  phosphate-buffered saline, pH 7.4).
Tumor transplanted hosts usually survive for 19–21 days.
The maintenance and use of the mice and the exper-
imental protocol of the present study was approved by
the Institutional Ethical Committee of North-Eastern Hill
University, Shillong, India.
2.3. Drug treatment schedule and antitumor activity
Therapeutic dose of cisplatin against malignant tumors
has been established to be 8–10 mg/kg body weight [2,35].
Thus, based on earlier studies [36] the dose of cisplatin
(10 mg/kg body weight) was  used in present studies. Sim-
ilarly, the dose of AA was  selected to be 1% in drinking
water which has already been standardized as an effec-
tive dose [12,37]. Tumor transplanted mice were randomly
divided into four groups consisting of 10 mice in each
group. Group-I mice served as tumor-bearing control and
received normal saline only. Group-II mice were given 1%
AA through drinking water for 5 consecutive days start-
ing from the 5th day post-tumor transplantation. Based on
the volume of water intake, the AA intake was noted to
be about 17.65–19.20 mg/day/per animal. Group-III mice
were administered with a single dose of cisplatin (10 mg/kg
body weight) on the 10th day post-tumor transplantation.
Group-IV mice received AA through drinking water from
the 5th day post-tumor transplantation and were admin-
istered with cisplatin (i.p., 10 mg/kg body weight) on the
10th day of tumor growth.
The anticancer efﬁcacy was determined as percentage
of average increase in life span (ILS) using the formula:
%ILS = (T/C × 100) − 100, where, T and C are the mean
survival days of treated and control groups of mice, respec-
tively. The same treatment schedule was followed for the
biochemical investigations in DL cells, liver, kidney and
testes. Ascites ﬂuid was collected from the peritoneal cav-
ity of mice in different groups and was  used to determine
the average tumor pH using a pH meter. The ascites ﬂuids
were then centrifuged and the pellets were used as DL cells.
2.4. Total reduced glutathione estimation
Total reduced glutathione (GSH) content was deter-
mined using the method of Sedlak and Lindsay [38]. Brieﬂy,
5% tissue homogenates of DL cells and tissues were pre-
pared in 0.02 mol/L EDTA (pH 4.7). 100 l of the tissue
homogenate or the pure reduced form of GSH was added
1.0 ml  of 0.2 mol/L Tris–EDTA buffer (pH 8.2). To this,
0.9 ml  of 0.02 mol/L EDTA (pH 4.7) with 20 l of Ellman’s
reagent (10 mmol/L DTNB in methanol) was  added. After
30 min  of incubation at room temperature, the reaction
mixtures were centrifuged and the absorbance of the clear
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upernatant was read at 412 nm.  The results were read
rom a standard curve prepared from 1 mmol/L solution of
educed glutathione.
.5. Catalase (EC 1.11.1.6) assay
Catalase activity was determined following the method
f Aebi [39]. A 10% tissue homogenate was prepared in 1%
riton X-100. The assay volume (3.0 ml)  contained 20 l of
issue supernatant as the enzyme source and 1.98 ml  of
0 mM phosphate buffer (pH 7.0) with 1.0 ml  of 30 mM
2O2. Catalase activity was measured by monitoring a
ecrease in absorbance of H2O2 at 240 nm.  The enzyme
ctivity was calculated using the extinction coefﬁcient
E240 = 0.0436 mM−1 cm−1), expressed as mol  of H2O2
ecomposed/min/mg protein.
.6. Determination of platinum content
The ascites tumor from different treatment groups of
ice were collected from the peritoneal cavity using a
.0 ml  disposable syringe and centrifuged at 5000 × g for
0 min, washed once in cold PBS (pH 7.4). The cell pellets
0.5 g) were digested in 5.0 ml  nitric acid and few drops
f hydrogen peroxide (H2O2) in a small clean conical ﬂask
ith gentle heating to near dryness. 5.0 ml  of perchloric
cid was added to the digests and again heated to near
ryness to remove excess nitric acid. This last step was
epeated until a clear solution resulted. The digests were
nally dissolved in distilled water maintaining the acid-
ty of approximately 5% and the ﬁltrates were stored in
olypropylene bottles for platinum analysis using a labtam
odel 8440 m plasma lab ICP-OES emission spectrome-
er operated at PMT  voltage 700 and wavelength 214.438
fter calibrating the instrument with appropriate standard
olutions.
.7. Lipid peroxidation assay
Lipid peroxidation (LPO) level was determined as
alondialdehyde (MDA) concentration following the
ethod of Buege and Aust [40]. Brieﬂy, 5% tissue
omogenate was prepared in 0.15 M KCl. To 1 ml of
he homogenate, 2 ml  of TCA–TBA–HCl reagent (15%
richloroacetic acid and 0.375% thiobarbituric acid dis-
olved in 0.25 N HCl) was added and mixed thoroughly.
fter 15 min  of heating in a boiling water bath, the mix-
ure was cooled at room temperature and centrifuged
1000 × g, 4 ◦C, 10 min) to remove the precipitate. The
bsorbance of the clear supernatant was read at 535 nm.
he MDA  concentration of the tissue sample was calculated
sing an extinction coefﬁcient of 1.56 × 105 M−1 cm−1 and
xpressed as nmol of MDA/mg protein.
.8. Histopathological evaluation
Liver, kidney and testes were collected from the mice
n different experimental groups on the 5th day post-
isplatin treatment and processed for histological appraisal
ollowing the methods described by Raghuramulu et al.
41]. Small tissue pieces were ﬁxed in Bouin’s ﬁxatives Reports 2 (2015) 489–503 491
(glacial acetic acid, 2.4 ml;  40% formaldehyde, 11.9 ml; sat-
urated picric acid, 35.7 ml)  for 24 h and were further routed
to prepare a solid parafﬁn block containing the tissue.
Parafﬁn-tissue sections (5 m in thickness) mounted on
clean glass slides were deparafﬁnised and stained with
hematoxylin–eosin stain. The stained sections were exam-
ined and photographed under a light microscope (Leica) to
analyze changes in overall cellular organization in different
tissues of the hosts under different treatment conditions.
2.9. Liver function test (LFT) and renal function test (RFT)
For the assessment of LFT, changes in the activity of
serum alkaline phosphatase (ALP), alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST) and for
kidney (renal) functions (RFT) measurement of serum urea
and creatinine levels of the hosts under different treat-
ment conditions were determined. Blood was collected
from the same mice group used for histological studies.
The measurement of these biochemical parameters was
done in Clinical chemistry analyzer (SYNERGY BIO-1904C)
at North-East Diagnostic Centre, Shillong.
2.10. Sperm abnormality assay
After 10 days of cisplatin treatment, male mice in differ-
ent groups were sacriﬁced and the cauda epididymis was
removed and minced into pieces in physiological saline.
It was  then kept undisturbed for 20 min  for diffusion of
spermatozoa. The spermatozoa were spread on a clean
slide, air-dried, ﬁxed in absolute methanol for 15 min and
then stained with 1% aqueous eosin-Y on the following day.
Five hundred sperms from each mouse were examined for
the abnormalities in sperm head and tail shapes follow-
ing the criteria as close as possible to those established by
Wyrobek and Bruce [42].
2.11. Statistical analysis
The results were expressed as the mean ± SD. Statistical
signiﬁcance was determined by one-way analysis of vari-
ance (ANOVA). The difference among multiple groups was
analyzed by a post hoc (Tukey test). A P-value ≤0.05 was
considered as statistically signiﬁcant.
3. Results
3.1. Antitumor activity
Following tumor transplantation, the increase in
abdominal size with sluggish movement of the animal was
noted from 3rd to 4th day onwards depicting an early
sign of tumor development. Control tumor transplanted
mice survived for about 19–21 days. The mean survival
time of mice treated with AA (group II) or cisplatin alone
was signiﬁcantly increased to about 34 days (ILS ∼ 79%)
and 42 days (ILS ∼ 122%) respectively. However, the hosts
survivability was further increased to more than 46 days
(ILS ∼ 142%) in combination treated group (Table 1, Fig. 1A
and B). Signiﬁcant decrease in the body weight and in tumor
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Table 1
Hosts survivability, tumor size and body weight of tumor-bearing mice under different treatment conditions.
Treatment groups Mean survival time (days) %ILS Tumor size (ml) on 20th day Body weight (g) on 20th day
Group I (control) 19.2 ± 1.9 – 11.2 ± 1.2 40.3 ± 1.5
Group II (AA) 34.5 ± 3.0* 79.68 6.9 ± 1.0* 35.1 ± 1.2*
Group III (cisplatin) 42.7 ± 3.4* 122.39 4.0 ± 0.8* 32.6 ± 1.1*
Group IV (AA + cisplatin) 46.6 ± 3.7*,a,# 142.71 2.9 ± 0.7*,a,# 28.7 ± 1.1*,a,#
Results are expressed as mean ± SD. Signiﬁcance of changes between control and different treated groups was  tested by one way ANOVA followed by Tukey
test,  n = 5, *P ≤ 0.05 as compared to the corresponding control; aP ≤ 0.05 as compared to AA; #P ≤ 0.05 as compared to cisplatin. Number of mice in each
group  = 10. Control = untreated tumor-bearing mice; AA = ascorbic acid; ILS = increase in life span.
umor-b
 groupsFig. 1. Survival pattern (A), and percent increase in life span (%ILS) (B), of t
as  mean of 5 independent experimental sets. Number of mice in each
AA  = ascorbic acid.
size of mice was observed after combination treatment as
compared to AA or cisplatin alone treatment (Table 1).
As compared to the pH of ascites tumor in control
group, the pH under different treatment conditions (i.e.,
AA, cisplatin and AA plus cisplatin) showed a time depen-
dant decrease during 24–96 h of treatment. As compared
to AA or cisplatin alone treatment group’s pH, signiﬁcant
decrease in the tumor pH was recorded in the combination
treated mice during 48–96 h (Fig. 2).
Fig. 2. Changes in the tumor pH at different treatment conditions. Results
are expressed as mean ± SD. ANOVA, n = 3, *P ≤ 0.05 as compared to the
corresponding control; aP ≤ 0.05 as compared to AA; #P ≤ 0.05 as com-
pared to cisplatin. Control = untreated tumor-bearing hosts; AA = ascorbic
acid.earing mice in control and different treated groups. Results are expressed
 = 10. Control = tumor-bearing mice without AA or cisplatin treatment;
3.2. Platinum content
Intracellular accumulation of platinum (drug) in DL  cells
showed that the platinum content was more initially at
24 h of treatment and decreased gradually during 48–96 h
in both cisplatin alone and combination treated group. As
compared to AA alone or cisplatin alone treatment, plat-
inum content was  more in tumor cells after combination
treatment of AA plus cisplatin (Fig. 3).
Fig. 3. Accumulation of platinum in Dalton’s lymphoma (DL) cells after
cisplatin or AA plus cisplatin treatment in in vivo. Results are expressed as
mean ± SD. ANOVA, n = 3, #P ≤ 0.05 as compared to cisplatin. AA = ascorbic
acid; ppb = parts per billion.
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Table  2
Changes in the total GSH content (mol/g wet  wt.) in the tissues of normal and tumor-bearing mice under different treatment conditions.
Treatment groups Liver Kidney Testes DL cells
Normal 13.40 ± 0.43 8.51 ± 0.73 10.61 ± 0.24 –
Control
24  h 12.11 ± 0.46 8.43 ± 0.31 09.82 ± 0.24 4.42 ± 0.36
48  h 11.58 ± 0.33 8.19 ± 0.23 09.58 ± 0.27 4.35 ± 0.22
72  h 11.33 ± 0.45 7.93 ± 0.36 09.23 ± 0.28 4.31 ± 0.19
96  h 11.19 ± 0.19 7.85 ± 0.22 09.15 ± 0.30 4.28 ± 0.21
AA  treated
24 h 11.83 ± 0.60* 6.47 ± 0.35* 08.28 ± 0.23* 3.31 ± 0.27*
48  h 11.38 ± 0.22 6.65 ± 0.28* 08.36 ± 0.31* 3.60 ± 0.25*
72  h 10.19 ± 0.32* 7.38 ± 0.34 08.78 ± 0.35 4.02 ± 0.19
96  h 11.03 ± 0.31 7.59 ± 0.32 08.85 ± 0.29 4.18 ± 0.26
Cisplatin treated
24 h 10.87 ± 0.29* 7.04 ± 0.35* 08.46 ± 0.27* 3.40 ± 0.23*
48  h 10.52 ± 0.26* 6.74 ± 0.34* 08.53 ± 0.22* 3.65 ± 0.17*
72  h 09.91 ± 0.34* 7.16 ± 0.28* 08.74 ± 0.25* 3.85 ± 0.18*
96  h 10.31 ± 0.25* 7.39 ± 0.24 09.06 ± 0.29 4.13 ± 0.18
AA  + cisplatin treated
24 h 10.55 ± 0.25*,a 6.76 ± 0.31*,a 09.17 ± 0.24*,a,# 3.11 ± 0.17*
48  h 10.69 ± 0.23*,a 6.90 ± 0.30* 09.04 ± 0.34*,# 3.39 ± 0.21*
72  h 10.78 ± 0.25*,a,# 7.62 ± 0.25# 09.31 ± 0.27*,# 3.54 ± 0.16*,#
96 h 10.93 ± 0.27# 7.78 ± 0.24# 09.50 ± 0.30 3.83 ± 0.19*,a,#
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ontrol; aP ≤ 0.05 as compared to AA; #P ≤ 0.05 as compared to cisplatin
umor-bearing mice; AA = ascorbic acid; DL = Dalton’s lymphoma.
.3. Reduced glutathione (GSH)
As compared to the GSH level in the tissues of normal
ice, the GSH level decreased in the corresponding tis-
ues of tumor-bearing control mice. AA alone treatment
howed a decrease in GSH level in different tissues and DL
ells during 24–48 h of treatment. Cisplatin treatment of
umor-bearing mice resulted in a signiﬁcant decrease in
SH level in liver during 24–96 h and in kidney, testes and
L cells during 24–72 h of treatment. As compared to AA
lone, combination treatment caused signiﬁcant increase
n GSH level in liver (72 h), kidney (24 h) and testes (24 h)
hile a decrease was noted in DL cells at 96 h of treatment.
s compared to cisplatin alone, AA plus cisplatin treatment
aused a signiﬁcant increase in GSH levels in liver and kid-
ey at 72–96 h, and in testes during 24–72 h of treatment.
owever, DL cells showed a signiﬁcant decrease in GSH
evels at 24–72 h of treatment (Table 2).
.4. Catalase (EC 1.11.1.6) activity
As compared to corresponding control, AA alone treat-
ent showed a signiﬁcant decrease in CAT activity in liver
nd kidney at 72 h and in DL cells at 24–72 h of treatment
espectively. Cisplatin treatment of tumor-bearing mice
aused a time dependent decrease in catalase activity in
iver, kidney and DL cells at 24–96 h and in testes during
4–72 h of treatment (Fig. 4A–D). As compared to cisplatin
lone, combination treatment of mice caused an increase
n catalase activity in liver and kidney during 24–72 h and
n testes at 72 h (Fig. 4A–D). However, signiﬁcant decrease
n catalase activity in DL cells was noted at 24–72 h of com-
ination treatment (Fig. 4A–D).VA, followed by Tukey test. *P ≤ 0.05 compared to the corresponding
l = hosts without tumor or any treatment condition; control = untreated
3.5. Lipid peroxidation (LPO)
As compared to malondialdehyde (MDA) level, i.e.,  lipid
peroxidation in the liver, kidney and testes of normal mice,
LPO level increased in liver and kidney of tumor-bearing
mice while a decrease was  observed in testes. As compared
to control cisplatin treatment caused an increase in LPO
in liver, kidney and DL cell at different time points. How-
ever, in testes decrease in LPO was  observed after cisplatin
treatment (Table 3). As compared to AA, combination treat-
ment caused a decrease in LPO in liver and kidney while an
increase was noted in DL cells at 24–48 h. As compared to
cisplatin alone, combination treatment of mice caused a
decrease in the LPO level in liver during 24–96 h and in
kidney, testes and DL cells during 48–96 h of treatment
(Table 3).
3.6. Histopathological changes
Histopathological examination of kidney in control mice
showed normal renal glomeruli and tubules having intact
epithelial cells. Ascorbic acid treatment showed almost
similar histological features as observed for control group
(Fig. 5A and B). However, cisplatin treatment of mice
caused close to grade 2 damages in kidney represented by
glomerular atrophy, inﬁltration of cells and tubular con-
gestions (Fig. 5C) which supports the view that cisplatin
alone treatment caused nephrotoxicity in the host. How-
ever, combination treatment of AA plus cisplatin in the
hosts led to a reduction in damages close to grade 1 in
renal tubular cells with lesser glomerular damages (Fig. 5D,
Table 4).
Liver sections from control mice showed normal
arrangement of hepatocytes and proper central vein
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Fig. 4. Changes in the activity of catalase (mol/min/mg protein) in the liver (A), kidney (B), testes (C) and DL cells (D), at different treatment conditions.
Results  are expressed as mean ± SD. ANOVA, n = 3, *P ≤ 0.05 as compared to the corresponding control; aP ≤ 0.05 as compared to AA; #P ≤ 0.05 as compared
to  cisplatin. Control = untreated tumor-bearing mice; AA = ascorbic acid.
Table 3
Changes in the level of malondialdehyde concentration (nmol/mg protein) reﬂecting lipid peroxidation in the tissues of normal and tumor-bearing mice
under  different treatment conditions.
Treatment groups Liver Kidney Testes DL cells
Normal 0.309 ± 0.018 0.291 ± 0.060 0.447 ± 0.029 –
Control
24  h 0.347 ± 0.043 0.361 ± 0.025 0.376 ± 0.021 0.124 ± 0.019
48  h 0.356 ± 0.025 0.387 ± 0.030 0.383 ± 0.022 0.120 ± 0.016
72  h 0.407 ± 0.031 0.411 ± 0.021 0.394 ± 0.025 0.117 ± 0.015
96  h 0.425 ± 0.032 0.441 ± 0.028 0.370 ± 0.032 0.106 ± 0.016
AA  treated
24 h 0.329 ± 0.044 0.351 ± 0.025 0.184 ± 0.025* 0.142 ± 0.019
48  h 0.332 ± 0.031 0.419 ± 0.028 0.169 ± 0.030* 0.156 ± 0.024
72  h 0.383 ± 0.025 0.403 ± 0.031 0.155 ± 0.032* 0.161 ± 0.019*
96  h 0.391 ± 0.035 0.372 ± 0.031* 0.162 ± 0.026* 0.158 ± 0.020*
Cisplatin treated
24 h 0.355 ± 0.028 0.452 ± 0.025* 0.248 ± 0.031* 0.196 ± 0.020*
48  h 0.396 ± 0.030* 0.469 ± 0.030* 0.269 ± 0.030* 0.209 ± 0.015*
72  h 0.474 ± 0.031* 0.428 ± 0.032 0.323 ± 0.041* 0.202 ± 0.018*
96  h 0.443 ± 0.033 0.397 ± 0.023 0.315 ± 0.024* 0.203 ± 0.017*
AA  + cisplatin treated
24 h 0.271 ± 0.026*,a,# 0.414 ± 0.023*,# 0.219 ± 0.031* 0.167 ± 0.017*,a
48 h 0.314 ± 0.024# 0.391 ± 0.031# 0.197 ± 0.021*,# 0.179 ± 0.018*,a,#
72 h 0.352 ± 0.032*,# 0.360 ± 0.028*,# 0.189 ± 0.029*,# 0.154 ± 0.020#
96 h 0.379 ± 0.030# 0.344 ± 0.030* 0.206 ± 0.023* 0.148 ± 0.018*,#
 by ANO
pared to
 lymphoValues represent mean ± SD, n = 3. Signiﬁcance of difference was tested
corresponding control; aP ≤ 0.05 as compared to AA; #P ≤ 0.05 as com
control = untreated tumor-bearing mice; AA = ascorbic acid; DL = Dalton’s
(Fig. 6A). As compared to control, AA treatment did
not show much change in the histological features of
liver (Fig. 6B). In contrast, treatment of mice with cis-
platin exhibited severe hepatotoxicity characterized by
diffused sinusoidal distortion, congestion in central veinVA followed by Tukey test, *P ≤ 0.05, signiﬁcance as compared to the
 cisplatin. Normal = hosts without tumor or any treatment condition;
ma.
and marked zonal hepatocytes damages (Fig. 6C). How-
ever, combination treatment of AA plus cisplatin in
the hosts showed mild to moderate damage of hepato-
cytes indicating recovery in the damaged cells (Fig. 6D,
Table 4).
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Fig. 5. Histological features of kidney from mice in control and different treated groups. (A) Control and (B) AA alone showing intact glomerular (regular
arrow)  and tubular (dotted arrow) arrangement, (C) cisplatin alone treatment, showing damaged tubules (dotted arrow), congested vein and degenerate
glomeruli, and (D) ascorbic acid (AA) plus cisplatin treatment, showing reduced damages in glomerular (regular arrow) and tubular cells (dotted arrow).
Scale  bar = 50 m.
Table 4
Histological damages graded according to pathological characterization for kidney, liver and testes of tumor-bearing mice under different treatment
conditions.
Tissue Parameters Treatments
Control AA Cisplatin AA + cisplatin
Kidney Tubular congestion − − ++++ ++
Tubular cast − − ++ +
Epithelial disquamation − − +++ +
Glomerular congestion − − +++ +
Blood vessel congestion − − ++++ ++
Hyperaemia of medullary part − − ++ +
Liver Haemorrhage − − ++++ +
Perinuclear clumping of
cytoplasm
− − +++ +
Hepatic vacuolation − − +++ ++
PMN  inﬁltration − − +++ +
Testes Tubular atrophy − − +++ +
Sertoli cells vacuolation and
spermiogenic abnormalities
− − ++++ ++
Leydig cells hypertrophy − − +++ ++
 
− ); ++++,
m
m
(
p
z
(Degeneration/regression in
leydig cells
−
, Nil; +, low/minimal (<12%); ++, mild/moderate (<20%); +++, high (<40%
Histopathological observations of testes of control
ice revealed well-deﬁned seminiferous tubules, sper-
atogenic cells and leydig cells in interstitial tissueFig. 7A). AA alone treatment also showed similar regular
attern of cellular morphology with normal spermato-
oa seen lying in the lumen of seminiferous tubules
Fig. 7B). Cisplatin alone treatment caused vacuolization− ++++ ++
 very high/severe (>40%); PMN, polymorphonuclear leukocytes.
in sertoli cells or dense granules in the cytoplasm,
damaged seminiferous tubules and degeneration and
regression of leydig cells (Fig. 7C), while combination
treatment of AA plus cisplatin in the hosts showed an
improvement in spermatogenic cells, reduced vacuolated
tubules and less deranged spermatogonial mass (Fig. 7D,
Table 4).
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treated 
ng featu
ix); (D) aFig. 6. Histological features of liver from mice in control and different 
arrow)  and proper central vein (asterix); (B) AA alone treatment, showi
hepatocytes damage (regular arrow) and congestion in central vein (aster
hepatic cells (regular arrow). Scale bar = 50 m.
3.7. Renal function test (RFT) and liver function test (LFT)
3.7.1. RFT
Serum urea and creatinine level were studied to further
monitor the renal toxicity in the hosts. AA alone treatment
also did not show any appreciable variation as compared
to the control. Cisplatin-treated mice showed signiﬁcant
elevation in serum urea and creatinine levels. The increase
in serum urea and creatinine level was about ∼270% and
∼302%, respectively (Fig. 8). However, as compared to cis-
platin alone, treatment of tumor-bearing mice with AA plus
cisplatin signiﬁcantly brought down the elevated levels of
serum urea (∼67%) and creatinine (∼66%) (Fig. 8).
3.7.2. LFT
The activity of serum alkaline phosphatase (ALP),
alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) were studied to assess hepatotoxicity in the
hosts under different treatment conditions. Here also,
AA alone treatment did not show any appreciable varia-
tion. Signiﬁcant increase in ALP (∼84%), ALT (∼37%) and
AST (∼601%) activities were observed after cisplatin alone
treatment (Fig. 8). However, as compared to cisplatin alone,
combination treatment caused signiﬁcant decrease in ALP
(∼11%), ALT (∼9%) and AST (∼330%) activity (Fig. 8).3.8. Sperm abnormality assay
Comparative analysis of sperm abnormalities in mice
treated with cisplatin alone showed maximum increasegroups. (A) Control, showing normal hepatocytes arrangement (regular
res as that of control; (C) cisplatin alone treatment, showing locational
scorbic acid (AA) plus cisplatin treatment, showing recovery of damaged
(∼34%) in the frequency of sperm abnormalities. AA treat-
ment did not show any signiﬁcant changes in the incidence
of sperm abnormalities. However, pre-treatment of mice
with AA in combination treatment signiﬁcantly decreased
(∼20%) the frequency of cisplatin-induced sperm abnor-
malities in the hosts (Table 5). Various types/shapes of
observed sperm abnormalities included hookless head,
looping mid-piece, microhead, balloon-like head, dou-
ble tailed, incorrect head–neck connection, diffused head,
banana head, amorphous head, etc. (Table 5).
4. Discussion
Cisplatin is one of the well-known potent cancer
chemotherapeutic agents, displaying clinical usefulness
against a wide variety of cancers [8]. Various reports
suggest that combination of different drugs/agents could
be more effective in cancer therapy and at the same
time reducing side effects in the host. Ascites Dalton’s
lymphoma has been used as a common experimental
malignant tumor to evaluate the antitumor activity of dif-
ferent drugs such as plant extracts [43,44], cantharidin [45],
cyclophosphamide [12], chlorambucil [46] and cisplatin
[35]. The ﬁndings from the present studies showed that the
Dalton’s lymphoma (DL) ascites-bearing mice treated with
AA or cisplatin alone depicted the increase in mean sur-
vival time of the hosts to about 79% and 122%, respectively
while combination treatment of AA plus cisplatin it further
increased to about 142% (Table 1, Fig. 1B). The increase in
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Fig. 7. Histological features of testes in control and different treated groups. (A) Control, showing well-deﬁned seminiferous tubules (regular arrow) and
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A
feydig cell (dotted arrow); (B) AA alone treatment, showing normal sperm
ith  vacuolated sertoli cells (arrow head) and degenerated leydig cells (do
arrow head) with less deranged spermatogonial mass (regular arrow) an
urvivability of the hosts was accompanied by a decrease
n tumor size as well as body weights in different treated
roups showing maximum decrease in tumor size and body
eight after combination treatment (Table 1). This may
uggest that as compared to AA or cisplatin alone, AA plus
isplatin combination treatment could be a better thera-
eutic strategy against murine ascites Dalton’s lymphoma.
ombination of ascorbic acid with other pharmacological
ig. 8. Changes in the parameters of renal function test (RFT) and
iver  function test (LFT) in tumor-bearing mice at different treat-
ent conditions. Results are expressed as mean ± SD, n = 3. ANOVA,
P ≤ 0.05 as compared to AA; #P ≤ 0.05 as compared to cisplatin.
A  = ascorbic acid, ALP = alkaline phosphatase, ALT = alanine aminotrans-
erase, AST = aspartate aminotransferase.(regular arrow); (C) cisplatin alone treatment, showing damaged tubules
w); (D) AA plus cisplatin treatment, showing reduced vacuolated tubules
 cells damage (dotted arrow). Scale bar = 50 m.
agents such as cyclophosphamide [12] and chlorambucil
[46] have also been reported to exhibit enhanced antitumor
activity against ascites Dalton’s lymphoma as compared to
drug alone. Similar ﬁndings have been reported using other
cancer models also where it has been observed that phar-
macological doses of ascorbic acid enhanced the effects of
arsenic trioxide on ovarian cancer cells [47], gemcitabine
on pancreatic cancer cells [48] and combination treatment
of gemcitabine and epigallocatechin-3-gallate (EGCG) on
mesothelioma cells [49]. The combinatorial treatment of
ascorbic acid and paclitaxel against H1299 (a non-small cell
lung cancer cell line) and BALB/c mice implanted with or
without sarcoma 180 cancer cells showed that the anti-
cancer effects of the combinational treatment were up to
1.7-fold higher than those of single-agent paclitaxel treat-
ment [13].
Extracellular acidosis is frequently associated with
tumor growth. Due to elevated production of lactic acid as
a result of anaerobic glycolysis, the microenvironment in
cancer cells are known to be acidic and intrinsically hypoxic
relative to normal tissues [50]. Such acidic environment
and also the nature of drugs greatly inﬂuence the response
of cancer cells to various treatments [51]. For instance,
the acidic extracellular pH increases the cellular uptake
of weakly acidic drugs such as cyclophosphamide and cis-
platin, thereby increasing the effect of these drugs, whereas
the acidic extracellular pH retards the uptake of weakly
basic drugs such as doxorubicin and vinblastine, thereby
reducing the effect of the drugs [52]. Here also, the decrease
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Table 5
Quantitative analysis of various types of sperm abnormalities induced after different treatment conditions.
Treatment
groups
Hookless Looping
mid-piece
Microhead Balloon-
like
Double
tailed
Incorrect
head–neck
connection
Diffused
head
Banana
head
Amorphous
head
Total
abnormal
sperms
AA treated 1 0 1 1 0 0 0 2 2 7
Cisplatin
treated
6  1 3 2 2 1 3 9 7 34
1 
0th dayAA  + cisplatin
treated
3 1 2 1 
Data are shown over percent control. Sperm analysis was carried out on 1
in tumor pH noted especially after combination treatment
of AA plus cisplatin (Fig. 2) may  facilitate the antitumor
activity of cisplatin and resulting in an increase in host
survivability (Fig. 1). It has been established that hypoxic
environment up regulates a number of transcription factors
such as HIF-1 [53]. HIF-1 has been demonstrated to acti-
vate transcription of as many as 70 genes including glucose
transporters and glycolytic enzymes, which may  account
for the increased anaerobic glycolysis and resultant acidiﬁ-
cation of tumors under a hypoxic environment [54]. It has
also been observed that exposure of tumor cells to a low
pH medium elevates p53 and p21 expression [55].
The cytotoxic activity of cisplatin may  also be corre-
lated with the amounts of platinum and its binding to
DNA [56]. The accumulation of platinum (drug) in DL cells
was noted to be more during 24 h which decreased later
during 48–96 h of different treatment conditions (Fig. 3).
This may  be due to its export from the cells and may
also be correlated with the recovery of GSH levels dur-
ing the later period (Table 2). The availability of more
drugs during initial stage of treatment may  be thought
to give rise to various metabolic dysfunctions directly or
indirectly related to cisplatin cytotoxicity which may  be
partially repaired or retained within the DL cells, lead-
ing to tumor regression. It was observed that combination
treatment signiﬁcantly increased the amount of platinum
(drug) in DL cells (Fig. 3) which could be an important
contributory factor in resulting better cytotoxic effects dur-
ing combination treatment against murine ascites Dalton’s
lymphoma and it is aided by decreased GSH levels in tumor
cells as observed in the present study (Table 2). Combi-
nation treatment of AA and H2O2 has been reported to
cause a signiﬁcant decrease in GSH levels in the mouse
neuroblastoma cells leading to effective death of cancer
cells [57]. Increased cisplatin-induced apoptosis has been
reported in ascorbate-supplemented cells by upregula-
tion of MLH1 and p73 gene [58]. It has been suggested
that ascorbic acid increases tumor cell membrane perme-
ability to chemotherapeutic drugs and helps to increase
the uptake of chemotherapy drugs into cancer cells [23].
It has also been suggested that ascorbic acid-mediated
sensitization of cancer cells to chemotherapy treatments
involves enhancement of membrane transport systems or
the activation of tumor suppressor genes [23]. Therefore,
the observed further decrease in GSH level in tumor cells
after combination treatment of AA plus cisplatin (Table 2)
as compared to AA or cisplatin alone may  help to enhance
its cytotoxic effects, thereby increasing tumor cells’ sus-
ceptibility to cell death. In fact changes in the intracellular0 1 5 6 20
 of cisplatin treatment. AA = ascorbic acid.
GSH levels could also affect the drug uptake by DL cells. In
study using freshly isolated peripheral blood mononuclear
cells, it has been reported that the increased intracellular
GSH concentration is correlated with decreased platinum-
DNA binding [59]. It has been well established that cisplatin
is detoxiﬁed by conjugation with GSH followed by the
export of the conjugate by the GS-X pump [60]. Hence, the
enhancement of cisplatin-induced tumor inhibition may
be due to modulation of permeability of tumor cell mem-
brane by ascorbic acid, causing an increase in the uptake
of cisplatin into tumor cells and making the DNA repair
machinery less efﬁcient due to more adduct formation in
the DNA which could also be assisted by decreased GSH
level (Table 2). Depletion of cellular GSH by buthionine sul-
foximine (BSO) has been shown to sensitize tumor cells to
oxidative stress, irradiation and certain chemotherapeu-
tic agents’ in in vitro [61,62]. Elevation of GSH in cellular
resistance to platinum agents has been reported in several
human and murine tumor cell lines [63].
Catalase is an endogenous antioxidant enzyme that neu-
tralizes ROS by converting H2O2 into H2O and O2 and
thus protects cells from oxidative damage [64]. As com-
pared to the corresponding control or AA treatment, it was
observed that cisplatin alone or AA plus cisplatin treatment
notably caused a signiﬁcant decrease in catalase activity in
DL cells (Fig. 4D) which may  result in its decreased abil-
ity to scavenge toxic hydrogen peroxides thereby increase
production of ROS and oxidative stress and may also cause
enhanced LPO (Table 3) in DL cells to facilitate its death.
The ﬁndings are in agreement with the earlier reports
on induced LPO and decreased catalase activity by treat-
ment with anticancer drugs [65,66]. Negahdar et al. [67]
reported that low levels of catalase activity in breast can-
cer resulted in higher production of ROS due to inadequate
enzyme activity to detoxify high levels of hydrogen perox-
ide thereby, leading to formation of hydroxyl radicals. Low
levels may  be due to treatment by anticancer drugs which
reduces antioxidants and induces oxidative stress [68].
Histopathological evaluations are commonly used for
detecting organ-speciﬁc effects related to chemical expo-
sure [69,70]. Ascorbic acid treatment showed almost
similar histological features of kidney, liver and testis as
observed for control group (Figs. 5–7, Table 4). Analysis of
comparative histological changes in kidney revealed that
cisplatin treatment caused destruction of the renal tubu-
lar cells close to grade 2 damages (Fig. 5C, Table 4), and
in liver it showed sinusoidal distortion and marked zonal
hepatocytes damage (Fig. 6C, Table 4). Some studies have
suggested that oxidative stress plays an important role
xicology
i
e
a
c
i
k
p
t
i
t
s
r
a
m
r
w
[
c
t
t
t
t
m
a
t
a
h
w
m
t
a
d
[
t
b
r
h
i
l
d
i
u
g
i
d
R
t
i
c
t
t
a
p
e
t
A
c
p
oA. Longchar, S.B. Prasad / To
n cisplatin-induced tissue damage [71–73] resulting in
nhanced production of ROS by decreasing the activity of
ntioxidant enzymes [74] and by depleting intracellular
oncentrations of GSH [75]. The decrease in catalase activ-
ty (Fig. 4) and GSH concentration (Table 2) particularly in
idney and liver after cisplatin treatment as observed in the
resent study may  be manifested in the enhanced oxida-
ive stress and pathogenesis of cisplatin-induced renal
njury and hepatocytes damage. The involvement of oxida-
ive stress in cisplatin-induced toxicity may  be further
upported by the fact that many antioxidants have been
eported to prevent cisplatin-induced nephrotoxicity [76]
nd hepatotoxicity [77]. Agents such as superoxide dis-
utase, dimethylthiourea and GSH have been shown to
educe the degree of renal failure and tubular cell damage
hen administered simultaneously with cisplatin in rats
78]. In the present study, AA alone did not show much
hanges in the histological features, however AA adminis-
ration prior to cisplatin injection showed amelioration in
he histopathological changes showing reduced destruc-
ion of renal tubular cells with lesser glomerular damage,
hus inferring nephroprotectivity (Fig. 5D), and mild to
oderate damage of hepatic cell indicating recovery of the
ltered tissue (Fig. 6D). Atasayar et al. [79] demonstrated
hat combined treatment of vitamin C and E with single
cute dose (toxic dose) of cisplatin is able to normalize the
istopathological alteration induced by cisplatin on kidney
hen compared with cisplatin alone treated group. The
echanisms by which ascorbic acid decreases the hepa-
otoxicity induced by cisplatin, is embodied in the fact that
scorbic acid might ameliorate the oxidative damage by
ecreasing LPO and altering antioxidant defense system
80,81].
Cisplatin-induced histopathological changes showing
oxicity in kidney and liver were substantiated by speciﬁc
iochemical changes in these tissues. Cisplatin has been
eported to increase serum urea and creatinine level in nep-
rotoxicity [82,83]. Cisplatin treatment caused an increase
n serum creatinine and urea levels (Fig. 8), with increased
ipid peroxides (Table 3) depletion of GSH (Table 2) and
ecrease in catalase activities (Fig. 4A–C). ROS have been
mplicated as important mediators of the acute renal fail-
re induced by cisplatin and other toxic agents, such as
entamicin and cyclosporin A [84]. The observed increase
n serum creatinine and urea levels (Fig. 8) may  also be
ue to decreased glomerular ﬁltration rate or increased
OS. It has been reported that administration of cisplatin
o rats incites nephrotoxicity, which was correlated with
ncreased creatinine and urea in plasma [65,85]. However,
ombination treatment with AA plus cisplatin decreased
he serum urea and creatinine level (Fig. 8), indicating
hat pre-treatment with ascorbic acid has a protective role
gainst cisplatin-induced nephrotoxicity. Its antioxidant
roperty to scavenge cisplatin-mediated free radicals gen-
ration may  also be involved in it.
Liver function tests (LFT) have been commonly used
o detect hepatic dysfunction [86] where assay of serum
LT, ALP and AST are the most frequently used hepato-
ellular markers to analyze hepatocellular injury. In the
resent study, hepatotoxicity induced by cisplatin was  rec-
gnized by the marked elevation in serum ALP, ALT and Reports 2 (2015) 489–503 499
AST enzymes activities (Fig. 8). However, these cisplatin-
induced elevations in enzyme activities were signiﬁcantly
attenuated by AA pre-treatment in combination group
thereby suggesting its hepatoprotective effect.
As an antioxidant agent, ascorbic acid and elevated level
of GSH in the tissues under combination treatment condi-
tion may  have a role to scavenge the reactive free radicals
in these tissues. Other studies have equally shown the pro-
tective role of ascorbic acid and other vitamins in hepatic
oxidative damage [87,88]. Thus, results of the present study
suggests ascorbic acid’s ameliorating effects to be likely
mediated via inhibition of free radicals generation and/or
free radical scavenging activity. The observed betterment
in histopathology as well as RFT and LFT along with the
recovery in GSH level in liver and kidney after combina-
tion treatment with AA plus cisplatin should be important
in its protective ability against cisplatin-induced liver and
kidney damage.
It is well known that, cytotoxic drugs depress sper-
matogenesis in mammals [89] by causing the death of the
developing germ cells in the seminiferous tubules. Cisplatin
based chemotherapy have led to persistent impairment
of fertility and leydig cell function in the majority of
patients with testicular cancer accompanied by signiﬁ-
cant reduction in sperm production [90]. In the present
study, degenerations in seminiferous tubules, intercellular
disassociation of germ cells, vacuolization in sertoli cells
and reduction in leydig cells were seen following cisplatin
treatment (Fig. 7C). The presence of vacuoles in seminifer-
ous tubules is an indicator of sertoli cells damage owing to
microtubule disruption [91,92]. Combination treatment of
mice with AA plus cisplatin revealed reduced vacuolated
tubules and less deranged spermatogonial mass (Fig. 7D,
Table 4). Other researchers have similarly reported that
combined pre-treatment with antioxidants including vita-
min  C can alleviate the damage caused to testis by lindane
[93]. Ascorbic acid has long been known to participate in
spermatogenesis process of rodents and ameliorate oxida-
tive stress related to testicular impairments in animals [94].
Moreover, dietary AA was found to protect against endoge-
nous oxidative DNA damage in human sperms [95]. Thus,
ascorbic acid pre-treatment may  be thought to enhance the
defense system during stress to combat tissue destruction
and safeguard cellular structure and function thereby, ame-
liorating cisplatin-induced testicular toxicity, as observed
for kidney and liver, in the hosts. Ascorbic acid has also been
reported to be effective in the protection of aluminium-
induced tissue toxicity in rabbits [96].
Cisplatin has been considered as a potent mutagen caus-
ing formation of abnormal male germ cells [97,98]. In the
present study, it was observed that treatment with cis-
platin caused a signiﬁcant increase in sperm abnormalities
in tumor-bearing male mice for 10 days when treated
alone and in combination with AA (Table 5). Among dif-
ferent treatment conditions, cisplatin caused maximum
(∼34%) abnormalities in the sperms suggesting that cis-
platin could reach the germ line cells and indicates its
potentiality as germ cell mutagen also. The development
in sperm abnormalities may  indicate that cisplatin induces
the DNA damage in germ cells leading to altered sperm
morphology [99]. Several studies indicate that various
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species of ROS generated through metal catalysis poten-
tially interact with gene strands causing mutations, thereby
inducing changes in sperm morphology [100–102]. There-
fore, the formation of abnormal sperm as observed in the
present study may  also be an oxidative stress dependent
phenomenon induced by cisplatin. However, combination
treatment with AA showed a signiﬁcant decrease (∼20%)
in the sperms abnormalities (Table 5). Ayinde et al. [103]
reported that daily consumption of vitamin C could be
useful in lowering oxidative stress and spermatozoa defor-
mations in lead exposed albino rats. It has also been
reported that co-administration of speman with cisplatin
showed signiﬁcant improvement on the sperm quantity
and quality along with enhanced steroidogenesis in mice
[104]. In fact the use of another antioxidant, i.e.,  melatonin
in combination with cisplatin has also shown chemopro-
tective effect against cisplatin-induced testicular toxicity
in rats [99] which also supports the present ﬁndings.
Therefore, the observed cisplatin-mediated decrease in
GSH level in the tissues, i.e.,  liver, kidney and testes (Table 2)
may  have a role in altering cellular antioxidant machinery
and in lessening the protective mechanism of tissues which
may  facilitate cisplatin-mediated toxic effect in these tis-
sues. Thus, the decreased level of GSH observed in testes
of tumor bearing mice (Table 2) should also be helping
to enhance cisplatin’s toxic/mutagenic effects in testes.
Although combination treatment caused a decrease in the
GSH level in the tissues during 24–72 h, GSH level was
restored to approximately control levels at 96 h (Table 2).
As GSH is known to play a role in detoxifying many reac-
tive metabolites, the increased GSH levels in the tissues
after combination treatment with AA plus cisplatin as com-
pared to cisplatin alone, could also represent a protective
mechanism in response to various toxic radicals, thereby,
suggesting the possible involvement of cellular GSH as
a mechanistic step in AA-mediated protection against
cisplatin-induced toxicity. Nagyová and Ginter [105] have
also reported the protective role of ascorbic acid in 2,4-
dichlorophenol induced teratogenic/carcinogenic toxicity
along with signiﬁcantly increased liver ascorbic acid and
GSH levels.
Lipid peroxidation (LPO) is a key process in many patho-
logical events and it is induced by oxidative stress. It is
regarded as one of the fundamental mechanisms of cellular
damage caused by free radicals having reacted with lipids
causing peroxidation that eventually results in the release
of products such as malondialdehyde (MDA), hydrogen
peroxide (H2O2) and hydroxyl radicals. All cellular com-
ponents are susceptible to attack by ROS, particularly by
hydroxyl radicals. Cisplatin treatment is associated with
induction of oxidative stress by generation of free radi-
cals and ROS [106,107]. In the present study, the increased
LPO level in the DL cells and tissues after cisplatin treat-
ment (Table 3) may  be attributed to antitumor activity
in DL cells and toxicity in tissues. However, in combi-
nation treatment, co-administration of AA and cisplatin
to mice signiﬁcantly decreased the level of LPO in liver,
kidney and testes (Table 3). The observed increase in cata-
lase activity in the tissues after combination treatment
(Fig. 4A–C) may  also be involved to lower LPO level and
play a compensatory regulatory role in decreasing cisplatin Reports 2 (2015) 489–503
alone-induced oxidative stress and toxicities in the tissues
of the host. These results imply that the increased activities
of catalase as well as increased concentration of reduced
GSH in the tissues after combination treatment of ascor-
bic acid plus cisplatin should be very helpful to decrease
cisplatin-induced toxicities involving excess hydrogen per-
oxide production and/or oxidative stress in the tissues of
the host.
5. Conclusions
From the present ﬁndings, it may  be suggested that
combination chemotherapy with dietary ascorbic acid and
cisplatin could be very useful in augmenting cisplatin-
mediated therapeutic efﬁcacy against murine ascites
Dalton’s lymphoma and other cancers in general, and at
the same time in decreasing cisplatin-induced toxicities
(nephrotoxicity, hepatotoxicity and testes/sperms abnor-
malities) in the hosts. However, the details of the molecular
mechanisms behind better therapeutic efﬁcacy and the
protective function of ascorbic acid in combination with
cisplatin treatment in the hosts needs further exploration.
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